Executive Director, Scientific Early Engagement and Cell & Gene Therapy
Labcorp
Greenfield, Indiana
Dr. Sikkema is currently Executive Director and Global Head, Scientific Early Engagement and Cell and Gene Therapy Bioanalysis for Labcorp.
Dan brings more than 30 years’ experience in the biopharmaceutical, vaccine and cell/gene therapy fields supporting oncology, neurosciences, respiratory, immunology and infectious disease. He has held positions of increasing responsibility at Bristol-Myers Squibb, Wyeth Vaccines, Merck Vaccines, Sanofi Pasteur, Frontage Laboratories, GlaxoSmithKline and Quanterix. In his career, he has contributed to the licensure of Prev(e)nar, Meningitec, Gardasil, RotaTeq, ProQuad, Zostavax, and Dengue vaccines, also Ofatumumab, Raxibacumab, Benlysta, Albiglutide, Mepolizumab, Denosumab, and other biopharmaceuticals, as well as Strimvelis (the world’s first ex vivo cell/gene therapy product). Dr. Sikkema holds a BS in Medical Technology from Northern Michigan University, and a PhD in Microbiology and Public Health from Michigan State University, College of Medicine, and he was a Post-Doctoral Fellow in Infectious Diseases at SUNY at Buffalo, School of Medicine. He has Chaired Division V (Clinical and Diagnostic Immunology) for American Society for Microbiology and was Coordinator for an Innovative Medicine Initiative project ABIRISK, the largest funded project to study Immunogenicity of Biotherapeutics. He has authored 30 peer-reviewed publications and has delivered more than 100 public presentations globally at scientific symposia.
Disclosure information not submitted.
Bioanalytics of New Drug Modalities and Cell/Gene Therapies
Monday, November 10, 2025
2:00 PM - 3:00 PM CT